細胞化驗分析和高內涵篩檢市場：按使用者和產品分類的預測 - 高階主管和顧問的指南（2026-2030 年）

報告摘要：

細胞化驗分析技術是藥物發現和科學研究的基石，目前該領域的研究活動正迅速發展。此外，新技術的進步使得細胞化驗分析能夠測量細胞功能的各個方面。預計該市場將持續成長，且成長勢頭強勁，絲毫沒有放緩的跡象。這項曾經是製藥業的核心技術，如今正成為生技領域的核心。

細胞化驗分析是生命科學研究、藥物發現和生物技術開發中的基礎技術。這些檢測方法利用活細胞來評估生物體對化合物、生物製藥、基因修飾或環境刺激的反應。透過測量細胞增殖、凋亡、受體活化、基因表現和代謝活性等細胞過程，細胞化驗分析能夠提供具有重要生理意義的見解，這對於理解疾病機制和開發新型療法至關重要。

全球細胞化驗分析市場規模估計每年超過180億至250億美元，預計未來十年將以約8%至11%的複合年成長率成長。這一成長主要得益於藥物研發活動的活性化、生物製劑產品線的擴展、細胞培養技術的進步以及高通量篩檢平台的日益普及。此外，對更具預測性的實驗模型的需求也推動了先進細胞化驗分析系統的應用。

細胞化驗分析廣泛應用於製藥、生物技術、學術研究和受託研究機構，用於評估藥物的療效、毒性和作用機制。與評估孤立分子標靶的生化檢測方法相比，這些檢測方法能夠提供更俱生物學相關性的資訊。隨著精準醫療和標靶治療的日益普及，對能夠評估複雜生物反應的功能性細胞檢測平台的需求也不斷成長。

在藥物發現和生物醫學研究中的作用

細胞化驗分析在藥物發現流程中發揮核心作用，它使研究人員能夠評估候選化合物與生物系統的相互作用。在早期篩檢項目中，細胞化驗分析通常用於識別具有理想生物活性的化合物。

功能性檢測用於評估候選藥物的效力、選擇性和毒性。基於細胞的毒性檢測有助於在藥物進入臨床開發之前識別出安全性不佳的化合物。

在癌症研究中，細胞化驗分析被廣泛用於評估癌細胞對治療藥物的反應。在免疫學研究中，細胞化驗分析被用來評估免疫細胞的活化、細胞激素的產生以及訊號路徑的活性。

在神經科學研究中，細胞化驗分析被用來研究神經訊號傳導機制和神經退化性疾病。

在幹細胞研究中，細胞化驗分析被用於研究細胞分化和組織發育。

細胞化驗分析廣泛應用於感染疾病調查中，用於評估宿主與病原體之間的相互作用。

生物技術公司利用細胞化驗分析來評估單株抗體和其他生物製藥的生物活性。

技術平台

細胞化驗分析融合了多種技術平台，旨在測量活細胞內的生物反應。

在報導基因分析中，利用基因改造的細胞來產生可測量的訊號，例如發光或螢光，以回應特定生物途徑的活化。

細胞活力和增殖試驗測量化合物對細胞生長和存活的影響。

訊號轉導分析用於評估細胞內訊號路徑的活化。

高內涵篩檢技術結合了自動化顯微鏡和影像分析軟體，可同時測量多個細胞參數。

流式細胞技術技術能夠根據蛋白質表現和細胞表面標誌物分析細胞群。

與傳統的2D細胞培養相比，3D細胞培養系統提供了更生理有效性的模型。

類器官技術使得研究源自幹細胞的組織樣結構成為可能。

微流體技術和晶片上的類器官系統模擬生理環境和細胞間相互作用。

自動化技術提高了可重複性，並實現了高通量篩檢工作流程。

市場促進因素

多種因素正在推動細胞化驗分析市場成長。

隨著藥物研發管線的擴展，對預測性臨床前試驗工具的需求也增加。

生物製藥和基因治療技術的進步推動了對功​​能性細胞檢測的需求不斷成長。

細胞培養技術的進步提高了實驗模型的生物學有效性。

高通量篩檢技術的日益普及推動了對檢測試劑盒和試劑的需求。

精準醫療方法的日益普及推動了對能夠評估複雜生物反應的檢測方法的需求。

學術研究經費的增加正在推動先進檢測技術的應用。

監管機構越來越重視證明治療產品的生物活性，這推動了經過驗證的細胞化驗分析的使用。

合約研究組織（CRO）的擴張支撐了對檢測服務的需求。

成像技術的進步使得測量複雜的細胞表現型成為可能。

市場區隔

細胞化驗分析市場可以按產品類型、最終用戶和地區進行細分。

按產品類型分類，試劑和檢測試劑盒由於持續的需求，佔據了市場收入的大部分。

最終用戶包括製藥公司、生物技術公司、學術研究機構和合約研究組織。

北美是重要的區域市場，這得益於其活躍的藥物研發活動和生物技術創新。

歐洲是一個重要的市場，擁有學術研究機構和製藥公司的支持。

由於對生命科學研發能力的投資增加，亞太市場正在擴張。

政府對生物醫學研究的資助推動了對細胞化驗分析技術的需求。

競爭格局

細胞化驗分析市場包括試劑供應商、細胞株供應商、檢測試劑盒製造商、儀器開發公司和受託研究機構。

競爭取決於檢測方法的可靠性、可重複性、易用性以及與自動化平台的兼容性。

各公司正日益開發將試劑、細胞株、檢測儀器和數據分析軟體結合的整合解決方案。

試劑供應商與製藥公司之間建立策略夥伴關係十分常見。

與細胞株和檢測技術相關的智慧財產權會影響競爭地位。

各公司正在投資開發先進的細胞模型，以更準確地再現人類生理功能。

高內涵篩檢技術已成為一個重要的創新領域。

將檢測技術與數據分析工具結合，可以提供競爭優勢。

未來展望

隨著藥物研究越來越依賴生物學上有效的實驗模型，細胞化驗分析市場預計將繼續擴張。

3D細胞培養和類器官技術的進步可能會提高臨床前試驗的預測準確性。

實驗室工作流程自動化可以提高實驗結果的重複性，並有可能降低每次實驗的成本。

人工智慧（AI）工具的使用可以提高複雜細胞資料集分析的準確性。

多體學技術和細胞化驗分析的整合有可能加深我們對疾病機制的理解。

基因治療和細胞治療產品線的擴展可能會增加對功能性細胞檢測的需求。

總體而言，細胞化驗分析是支持藥物發現和生物醫學研究的重要工具。細胞生物學技術、自動化平台和數據分析的不斷進步預計將推動市場持續成長。

目錄

第1章 市集指南

• 情境分析
  • 在藥物發現和生物醫學研究中發揮戰略作用
  • 技術複雜性和可重複性挑戰
  • 成本結構與工作流程效率
  • 3D細胞培養與先進模型的應用
  • 與高通量篩檢技術的整合
  • 生物製藥開發中的監管預期
  • 競爭格局與產業結構
  • 數據分析與解釋中的挑戰
  • 地理市場動態
  • 展望與戰略意義
• 高階主管和行銷負責人的指南
• 投資分析師和管理顧問指南
  • 人工智慧的影響

第2章：引言與市場定義

• 什麼是細胞化驗分析？
• 臨床試驗失敗
• 感染疾病發揮了更大的作用。
• 市場定義
• 調查方法
• 美國醫療保健市場及藥品研發成本展望

第3章：細胞化驗分析－技術指南

• 細胞培養
• 細胞分析
• 細胞活力檢測
• 細胞生長化驗
• 細胞毒性試驗
• 細胞老化檢測
• 細胞凋亡
• 自噬
• 壞死
• 氧化壓力
• 2D vs. 3D
• 訊號傳導通路，G蛋白偶聯受體
• 免疫調節和抑制
• 記者基因技術
• CBA設計與開發
• 細胞化驗分析—重點

第4章 行業概覽

• 參與企業充滿活力的市場
  • 學術研究辦公室
  • 合約研究組織（CRO）
  • 基因組測量設備供應商
  • 細胞分離與觀察設備供應商
  • 細胞株和試劑供應商
  • 製藥公司
  • 審計機構
  • 認證機構

第5章 市場趨勢

• 成長促進因素
• 成長阻礙因素
• 技術發展

第6章：細胞化驗分析的最新趨勢

第7章：主要細胞化驗分析公司簡介

• Abcam
• Agilent
• Aurora Biomed
• Axxam
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• Berkley Lights
• BioIVT
• Bio-Rad Laboratories, Inc.
• BMG Labtech
• Bruker
• Cell Biolabs, Inc.
• Cell Signaling Technology, Inc.
• Charles River Laboratories
• Corning, Inc.
• Cytek Biosciences
• Cytovale
• Deepcell
• Enzo Biochem
• Eurofins DiscoverX Corporation
• Evotec AG
• Excellerate Bioscience
• Fujifilm Cellular Dynamics International
• Genedata
• Hemogenix
• Invivogen
• Leica Biosystems
• Lonza Group Ltd.
• Luminex Corp（DiaSorin）
• Merck & Co., Inc
• Miltenyi Biotec
• Molecular Devices
• Nanion
• Ncardia
• New England Biolabs, Inc.
• Novogene Bioinformatics Technology Co., Ltd.
• Olympus
• Origene Technologies
• Promega
• Qiagen
• Reaction Biology
• Recursion Pharma
• Revvity
• Roche Diagnostics
• Sartorius
• Sartorius-ForteBio
• Sartorius-IntelliCyt
• Singleron Biotechnologies
• Sony Biotechnology
• SPT Labtech
• Stemcells Technologies Canada Inc.
• Tecan
• Thermo Fisher Scientific Inc.
• Vitro Biopharma

第8章 世界市場規模

• 全球各國市場概覽
• 全球市場概覽（按使用者類型分類）
• 全球市場概覽（按產品類別分類）

第9章：按使用者類型分類的全球市場

• 製藥
• 研究
• 行業/化妝品

第10章：依產品類別細胞化驗分析

• 裝置
• 試劑
• 服務
• 軟體

第11章附錄

表格一覽

圖表列表

Report Overview:

Cell Based Assays are a mainstay of drug development and scientific research, and now research activity is growing strongly. On top of this new technology is allowing Cell Based Assays to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.

Cell-based assays represent a foundational technology within life sciences research, drug discovery, and biotechnology development. These assays use living cells to evaluate biological responses to chemical compounds, biologics, genetic modifications, or environmental stimuli. By measuring cellular processes such as proliferation, apoptosis, receptor activation, gene expression, and metabolic activity, cell-based assays provide physiologically relevant insights that are critical for understanding disease mechanisms and developing new therapeutic products.

The global Cell-Based Assay market is estimated to exceed approximately USD 18-25 billion annually and is projected to grow at compound annual growth rates of approximately 8-11% over the next decade. Growth is driven by increasing pharmaceutical research and development activity, expansion of biologics pipelines, advances in cell culture technologies, and increasing use of high-throughput screening platforms. Demand for more predictive experimental models is also supporting increased adoption of advanced cell-based assay systems.

Cell-based assays are widely used across pharmaceutical, biotechnology, academic, and contract research organizations to evaluate drug efficacy, toxicity, and mechanism of action. These assays provide more biologically relevant information compared with biochemical assays that evaluate isolated molecular targets. Increasing emphasis on precision medicine and targeted therapeutics is further expanding demand for functional cellular testing platforms capable of evaluating complex biological responses.

Role in Drug Discovery and Biomedical Research

Cell-based assays play a central role in drug discovery workflows by enabling researchers to evaluate how candidate compounds interact with biological systems. Early-stage screening programs often rely on cell-based assays to identify compounds with desired biological activity.

Functional assays are used to evaluate potency, selectivity, and toxicity of candidate drug compounds. Cell-based toxicity assays can help identify compounds with unfavorable safety profiles before entering clinical development.

Cancer research relies heavily on cell-based assays to evaluate responses of tumor cells to therapeutic agents. Immunology research uses cell-based assays to evaluate immune cell activation, cytokine production, and signaling pathway activity.

Neuroscience research uses cell-based assays to study neuronal signaling and neurodegenerative disease mechanisms.

Stem cell research relies on cell-based assays to study cellular differentiation and tissue development.

Cell-based assays are also widely used in infectious disease research to evaluate host-pathogen interactions.

Biotechnology companies use cell-based assays to evaluate biological activity of monoclonal antibodies and other biologic drugs.

Technology Platforms

Cell-based assays incorporate a range of technology platforms designed to measure biological responses within living cells.

Reporter gene assays use genetically engineered cells to produce measurable signals such as luminescence or fluorescence in response to activation of specific biological pathways.

Cell viability and proliferation assays measure effects of compounds on cell growth and survival.

Signal transduction assays evaluate activation of intracellular signaling pathways.

High-content screening technologies combine automated microscopy with image analysis software to measure multiple cellular parameters simultaneously.

Flow cytometry technologies enable analysis of cell populations based on protein expression and cell surface markers.

3D cell culture systems provide more physiologically relevant models compared with traditional two-dimensional cell cultures.

Organoid technologies enable study of tissue-like structures derived from stem cells.

Microfluidics and organ-on-chip systems simulate physiological environments and cell-cell interactions.

Automation technologies improve reproducibility and enable high-throughput screening workflows.

Market Drivers

Several factors are driving growth in the cell-based assay market.

Expansion of pharmaceutical pipelines is increasing demand for predictive preclinical testing tools.

Growth in biologics and gene therapy development is increasing demand for functional cellular assays.

Advances in cell culture technologies are improving biological relevance of experimental models.

Increased adoption of high-throughput screening technologies is supporting demand for assay kits and reagents.

Increasing use of precision medicine approaches is driving demand for assays capable of evaluating complex biological responses.

Growth in academic research funding supports adoption of advanced assay technologies.

Increasing regulatory emphasis on demonstrating biological activity of therapeutic products supports use of validated cell-based assays.

Expansion of contract research organizations supports demand for assay services.

Advances in imaging technologies enable measurement of complex cellular phenotypes.

Market Segmentation

The cell-based assay market can be segmented by product type, end user, and geographic region.

By product type, reagents and assay kits represent a significant portion of market revenue due to recurring demand.

End users include pharmaceutical companies, biotechnology companies, academic research institutions, and contract research organizations.

North America represents a major regional market due to strong pharmaceutical research activity and biotechnology innovation.

Europe represents a significant market supported by academic research institutions and pharmaceutical companies.

Asia-Pacific markets are expanding due to increasing investment in life sciences research and drug development capabilities.

Government funding for biomedical research supports demand for cell-based assay technologies.

Competitive Landscape

The cell-based assay market includes reagent suppliers, cell line providers, assay kit manufacturers, instrument developers, and contract research organizations.

Competition is influenced by assay reliability, reproducibility, ease of use, and compatibility with automation platforms.

Companies are increasingly developing integrated solutions combining reagents, cell lines, detection instruments, and data analysis software.

Strategic partnerships between reagent suppliers and pharmaceutical companies are common.

Intellectual property related to cell lines and assay technologies may influence competitive positioning.

Companies are investing in development of advanced cellular models that better replicate human physiology.

High-content screening technologies represent an important area of innovation.

Integration of assay technologies with data analytics tools may provide competitive advantages.

Future Outlook

The cell-based assay market is expected to continue expanding as pharmaceutical research increasingly relies on biologically relevant experimental models.

Advances in 3D cell culture and organoid technologies may improve predictive accuracy of preclinical studies.

Automation of laboratory workflows may improve reproducibility and reduce cost per experiment.

Artificial intelligence tools may improve analysis of complex cellular datasets.

Integration of multi-omics technologies with cell-based assays may improve understanding of disease mechanisms.

Expansion of gene therapy and cell therapy pipelines may increase demand for functional cellular assays.

Overall, cell-based assays represent essential tools supporting drug discovery and biomedical research. Continued advances in cell biology technologies, automation platforms, and data analytics are expected to support sustained market growth.

Table of Contents

1 Market Guides

• 1.1 Situation Analysis
  • 1.1.1 Strategic Role in Drug Discovery and Biomedical Research
  • 1.1.2 Technological Complexity and Reproducibility Challenges
  • 1.1.3 Cost Structure and Workflow Efficiency
  • 1.1.4 Adoption of 3D Cell Culture and Advanced Models
  • 1.1.5 Integration with High-Throughput Screening Technologies
  • 1.1.6 Regulatory Expectations in Biopharmaceutical Development
  • 1.1.7 Competitive Landscape and Industry Structure
  • 1.1.8 Data Analysis and Interpretation Challenges
  • 1.1.9 Geographic Market Dynamics
  • 1.1.10 Outlook and Strategic Implications
• 1.2 Guide for Executives and Marketing Staff
• 1.3 Guide for Investment Analysts and Management Consultants
  • 1.3.1 Impact of Artificial Intelligence

2 Introduction and Market Definition

• 2.1 What are Cell Based Assays?
• 2.2 Clinical Trial Failures
  • 2.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays
• 2.3 Infectious Disease Will Play a Larger Role
• 2.4 Market Definition
  • 2.4.1 Market Size
  • 2.4.2 Currency
  • 2.4.3 Years
• 2.5 Methodology
  • 2.5.1 Methodology
  • 2.5.2 Sources
  • 2.5.3 Authors
• 2.6 U.S. Medical Market and Pharmceutical Research Spending - Perspective
  • 1.5.1 U.S. Expenditures for Pharmaceutical Research

3 Cell Based Assays - Guide to Technology

• 3.1 Cell Cultures
  • 3.1.1 Cell Lines
  • 3.1.2 Primary Cells
  • 3.1.3 Stem Cells
  • 3.1.4 iPSC's - The Special Case
• 3.2 Cell Assays
• 3.3 Cell Viability Assays
• 3.4 Cell Proliferation Assays
• 3.5 Cytotoxicity Assays
• 3.6 Cell Senescence Assays
• 3.7 Apoptosis
• 3.8 Autophagy
• 3.9 Necrosis
• 3.10 Oxidative Stress
• 3.11 2D vs. 3D
• 3.12 Signalling Pathways, GPCR
• 3.13 Immune Regulation & Inhibition
• 3.14 Reporter Gene Technology
• 3.15 CBA Design & Development
• 3.16 Cell Based Assays - The Takeaway

4 Industry Overview

• 4.1 Players in a Dynamic Market
  • 4.1.1 Academic Research Lab
  • 4.1.2 Contract Research Organization
  • 4.1.3 Genomic Instrumentation Supplier
  • 4.1.4 Cell Separation and Viewing Supplier
  • 4.1.5 Cell Line and Reagent Supplier
  • 4.1.6 Pharmaceutical Company
  • 4.1.7 Audit Body
  • 4.1.8 Certification Body

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 Candidate Growth
  • 5.1.2 Immuno-oncology
  • 5.1.3 Genomic Blizzard
  • 5.1.4 Technology Convergence
  • 5.1.5 The Insurance Effect
• 5.2 Factors Limiting Growth
  • 5.2.1 CBA Development Challenges
  • 5.2.2 Instrument Integration
  • 5.2.3 Protocols
• 5.3 Technology Development
  • 5.3.1 3D Assays
  • 5.3.2 Automation
  • 5.3.3 Software
  • 5.3.4 Primary Cells
  • 5.3.5 Signalling and Reporter Genes
  • 5.3.6 The Next Five Years

6 Cell Based Assays Recent Developments

• 6.1 Recent Developments
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 New cell-based Screening Panel
• 6.3 New platform will accelerate single-cell analysis workflow
• 6.4 CytoTronics Announces Pixel Octo
• 6.5 Cell Painting boosts high-throughput screening
• 6.6 Castle Biosciences Sees Big Gains in New Testing Niches
• 6.7 Cell-Based Assay Outperforms Others
• 6.8 3D spheroid model Monitors T-cell invasion
• 6.9 BioAuxilium Launches New Biomarker Assay
• 6.10 Charles River Laboratories Acquires SAMDI Tech
• 6.11 Axion BioSystems Launches New High-Throughput Live-Cell Imaging Platform
• 6.12 Fujifilm's Life Sciences Invests in PhenoVista Biosciences
• 6.13 Nucleai Launches New Multiplex Imaging Spatial Analysis Solution
• 6.14 BIO-TECHNE ANNOUNCES MULTI-OMIC RNASCOPE ASSAYS
• 6.15 Indivumed, CellPhenomics Partner on Cancer Drug Target Research
• 6.16 Synthego to Accelerate Drug Discovery
• 6.17 Long COVID Detected By Cell-Based Assay
• 6.18 Nanolive closes a USD 20 million Funding Round
• 6.19 Depixus Seeks to Commercialize 'Magnetic Tweezers' for Drug Discovery
• 6.20 BioAuxilium Research Expands its Cell Signaling Assay Portfolio
• 6.21 Droplet Genomics Debuts New Microfluidic Screening Platform
• 6.22 DLP Plus Single-Cell Sequencing Method Spreads From Canada to Cancer Labs Worldwide
• 6.23 Secondcell Bio to Make Creation of Cell Lines Easy
• 6.24 Nanolitre-scale cell assays developed with droplet microarraymass spec
• 6.25 Thermo Fisher Scientific Acquires Cell Sorting Technology
• 6.26 Cellink to Distribute Phasefocus High-Content Cell Imaging Platform
• 6.27 Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
• 6.28 Cancer Genetics to Acquire Organoid Startup Stemonix
• 6.29 Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
• 6.30 CRISPR Screens Uncover Novel Cancer Therapy Targets
• 6.31 ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam

7 Profiles of Key Cell Based Assay Companies

• 7.1 Abcam
• 7.2 Agilent
• 7.3 Aurora Biomed
• 7.4 Axxam
• 7.5 Beckman Coulter Diagnostics
• 7.6 Becton, Dickinson and Company
• 7.7 Berkley Lights
• 7.8 BioIVT
• 7.9 Bio-Rad Laboratories, Inc.
• 7.10 BMG Labtech
• 7.11 Bruker
• 7.12 Cell Biolabs, Inc.
• 7.13 Cell Signaling Technology, Inc.
• 7.14 Charles River Laboratories
• 7.15 Corning, Inc.
• 7.16 Cytek Biosciences
• 7.17 Cytovale
• 7.18 Deepcell
• 7.19 Enzo Biochem
• 7.20 Eurofins DiscoverX Corporation
• 7.21 Evotec AG
• 7.22 Excellerate Bioscience
• 7.23 Fujifilm Cellular Dynamics International
• 7.24 Genedata
• 7.25 Hemogenix
• 7.26 Invivogen
• 7.27 Leica Biosystems
• 7.28 Lonza Group Ltd.
• 7.29 Luminex Corp (DiaSorin)
• 7.30 Merck & Co., Inc
• 7.31 Miltenyi Biotec
• 7.32 Molecular Devices
• 7.33 Nanion
• 7.34 Ncardia
• 7.35 New England Biolabs, Inc.
• 7.36 Novogene Bioinformatics Technology Co., Ltd.
• 7.37 Olympus
• 7.38 Origene Technologies
• 7.39 Promega
• 7.40 Qiagen
• 7.41 Reaction Biology
• 7.42 Recursion Pharma
• 7.43 Revvity
• 7.44 Roche Diagnostics
• 7.45 Sartorius
• 7.46 Sartorius-ForteBio
• 7.47 Sartorius-IntelliCyt
• 7.48 Singleron Biotechnologies
• 7.49 Sony Biotechnology
• 7.50 SPT Labtech
• 7.51 Stemcells Technologies Canada Inc.
• 7.52 Tecan
• 7.53 Thermo Fisher Scientific Inc.
• 7.54 Vitro Biopharma

8 Global Market Size

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by User - Overview
  • 8.2.1 Table - Global Market by User
  • 8.2.2 Chart - Global Market by User - Base/End Year Comparison
  • 8.2.3 Chart - Global Market by User - Base Year
  • 8.2.4 Chart - Global Market by User - End Year
  • 8.2.5 Chart - Global Market by User - Share by Year
• 8.3 Global Market by Product Class - Overview
  • 8.3.1 Table - Global Market by Product Class
  • 8.3.2 Chart - Global Market by Product Class - Base/End Year Comparison
  • 8.3.3 Chart - Global Market by Product Class - Base Year
  • 8.3.4 Chart - Global Market by Product Class - End Year
  • 8.3.5 Chart - Global Market by Product Class - Share by Year

9 Global Market by User Type

• 9.1 Pharma
  • 9.1.1 Table Pharma - by Country
  • 9.1.2 Chart - Pharma Growth
• 9.2 Research
  • 9.2.1 Table Research - by Country
  • 9.2.2 Chart - Research Growth
• 9.3 Industry/Cosmetic
  • 9.3.1 Table Industry/Cosmetic - by Country
  • 9.3.2 Chart - Industry/Cosmetic Growth

10 Cell Based Assay by Product Class

• 10.1 Instrument
  • 10.1.1 Table Instrument - by Country
  • 10.1.2 Chart - Instrument Growth
• 10.2 Reagent
  • 10.2.1 Table Reagent - by Country
  • 10.2.2 Chart - Reagent Growth
• 10.3 Services
  • 10.3.1 Table Services - by Country
  • 10.3.2 Chart - Services Growth
• 10.4 Software
  • 10.4.1 Table Software - by Country
  • 10.4.2 Chart - Software Growth

11 Appendices

• 11.1 FDA Cancer Drug Approvals by Year
• 11.2 Clinical Trials Started
• 11.3 Share of Pharma R&D by Country

Table of Tables

• Table 1 The Large Variety of Cell Lines
• Table 2 Some Common Viability Assays
• Table 3 Oxidative Stress Related Diseases
• Table 4 Important Signalling Pathways
• Table 5 Market Players by Type
• Table 6 Five Factors Driving Growth
• Table 7 Three Factors Limiting Growth
• Table 8 - Global Market by Region
• Table 9 Global Market by User
• Table 10 Global Market by Product Class
• Table 11 Pharma by Country
• Table 12 Research by Country
• Table 13 Industry/Cosmetic by Country
• Table 14 Instrument by Country
• Table 15 Reagent by Country
• Table 16 Services by Country
• Table 17 Software by Country

Table of Figures

• Figure 1 Reasons for clinical Failure by Phase
• Figure 2 Immunotherapy Clinical Trial Growth
• Figure 3 Pharmaceutical Research Expenditures ($Billion)
• Figure 4 Oxidative Stress and Free Radical Toxicity
• Figure 5 FDA Cancer Drug Approvals
• Figure 6 The Changing Approach to Cancer Diagnostics
• Figure 7 Growth rates of Cell Based Assays by Product Class
• Figure 8 Global Market Share Chart
• Figure 9 Global Market by User - Base vs. End Year
• Figure 10 Global Market by User Base Year
• Figure 11 Global Market by User End Year
• Figure 12 User Share by Year
• Figure 13 Global Market by Product Class - Base vs. End Year
• Figure 14 Global Market by Product Class Base Year
• Figure 15 Global Market by Product Class End Year
• Figure 16 Product Class Share by Year
• Figure 17 Pharma Growth
• Figure 18 Research Growth
• Figure 19 Industry/Cosmetic Growth
• Figure 20 Instrument Growth
• Figure 21 Reagent Growth
• Figure 22 Services Growth
• Figure 23 Software Growth
• Figure 24 FDA Cancer Drug Approvals by Year
• Figure 25 Clinical Trials for Immunotherapy by Year
• Figure 26 Share of Pharma R&D by Country